Hepatitis C virus (HCV) infection is a major cause of end-stage liver disease, including decompensated cirrhosis and hepatocellular carcinoma. Over 95％ of patients with HCV infection have achieved sustained virologic response at 12 weeks under the treatment of several pan-genotypic regi-mens approved for patients with HCV infection. The gle-caprevir/pibrentasvir (G/P) regimen has some features that distinguish it from others and is the only 8-week regimen ap-proved for treatment-naive patients and patients experienced in regimens containing (peg)interferon, ribavirin, and/or so-fosbuvir, without an HCV NS3/4A protease inhibitor or NS5A inhibitor (except those with genotype 3). This review aims to summarize the efficacy and safety of G/P in HCV-infected pa-tients from clinic trials and real-world studies, including those who have historically been considered difficult to cure.